Alzheon reports biomarker results supporting ALZ‑801 effects in Alzheimer’s
Alzheon's ALZ-801 demonstrated sustained reductions in plasma phosphorylated tau 217 across Phase 2 and Phase 3 trials, with biomarker changes correlating to cognitive preservation and protection against hippocampal volume loss in early Alzheimer's disease. These results support the compound's mechanism of inhibiting neurotoxic amyloid oligomer formation at disease stages where intervention may be most effective.

